Differential proteomics analysis of oligodendrogliomas and astrocytomas using iTRAQ quantification
Author and article information
Abstract
Background: Astrocytomas and oligodendrogliomas are two types of primary Central nervous system (CNS) tumors. Because of the cytoarchitectural variability and lacking of accurate differential diagnosis biomarkers, distinguishing between these neoplasms remains a challenge. Method: In this study, we utilized the tumor tissue proteome to distinguish the astrocytomas and oligodendrogliomas. The protein samples from astrocytomas and oligodendrogliomas tumor tissues were analyzed by 2DLC/MS/MS and isobaric tags for relative and absolute quantitation (iTRAQ) quantification. The differential proteins were analyzed by IPA software, and three identified differential proteins were validated by Western Blot. Results: A total of 2189 proteins were identified, including 150 upregulated and 103 downregulated in astrogliomas compared to oligodendrogliomas. By bioinformatics analysis, compared to oligodendrogliomas, the astrocytomas is more likely tend to cell proliferation, migration and the tumor angiogenesis, indicating astrocytomas was more malignant than the oligodendrogliomas. Pathway analysis showed that members of Rho Family GTPases were remarkably changed between astrocytomas and oligodendrogliomas. Two member of Rho family of GTPases, Cell division control protein 42 homolog (CDC42) and Transforming protein RhoA (RHOA) were over-expressed in astrocytomas and oligodendrogliomas, respectively. Discussion: Above data indicated that the differential proteome could be useful to distinguish between astrocytomas and oligodendrogliomas, especially the Rho family of GTPases. Differential proteome could partially reflect the pathological characteristics of these two diseases.
Cite this as
2016. Differential proteomics analysis of oligodendrogliomas and astrocytomas using iTRAQ quantification. PeerJ Preprints 4:e2179v1 https://doi.org/10.7287/peerj.preprints.2179v1Author comment
This is a submission to PeerJ for review.
Sections
Supplemental Information
Distribution of proteins fold change in astrocytomas vs oligodendrogliomas
Supplementary Figure 1: Distribution of proteins fold change in astrocytomas vs oligodendrogliomas.
Qualitative protein list of oligodendrogliomas and astrocytomas proteome
Supplementary Table 1: Qualitative protein list of oligodendrogliomas and astrocytomas proteome.
Quantitative protein and peptide list of oligodendrogliomas and astrocytomas proteome
Supplementary Table 2: Quantitative protein and peptide list of oligodendrogliomas and astrocytomas proteome.
Differential proteins between oligodendrogliomas and astrocytomas
Supplementary Table 3: Differential proteins between oligodendrogliomas and astrocytomas .
Detail protein list classified by biological functions and pathway analysis by IPA in oligodendrogliomas and astrocytomas
Supplementary Table 4: Detail protein list classified by biological functions and pathway analysis by IPA in oligodendrogliomas and astrocytomas
Additional Information
Competing Interests
The authors declare that they have no competing interests.
Author Contributions
Shide Lin conceived and designed the experiments, prepared figures and/or tables.
Jingzhe Li performed the experiments, reviewed drafts of the paper.
Peng Wang performed the experiments, reviewed drafts of the paper.
Yujie Zang analyzed the data.
Fan Feng performed the experiments, analyzed the data, prepared figures and/or tables.
TingBao Zhao contributed reagents/materials/analysis tools, wrote the paper.
Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
Chinese PLA General Hospital Ethics Committee
S2014-096-01
Data Deposition
The following information was supplied regarding data availability:
Differential Proteomics analysis of Oligodendroglioma and Astrocytoma using iTRAQ quantifiction
https://figshare.com/s/1497b062604de715a297
Funding
The authors received no funding for this work.
